Avanos Medical Full Year 2023 Earnings: US$0.21 loss per share (vs US$1.08 profit in FY 2022)
Avanos Medical (NYSE:AVNS) Full Year 2023 Results
Key Financial Results
Revenue: US$673.3m (down 18% from FY 2022).
Net loss: US$9.90m (down by 120% from US$50.5m profit in FY 2022).
US$0.21 loss per share (down from US$1.08 profit in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Avanos Medical Earnings Insights
Looking ahead, revenue is forecast to grow 4.0% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are up 3.8% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. See our latest analysis on Avanos Medical's balance sheet health.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
